FindTrial
Sign In

Effect of high dose intravenous vitamin C on moderate novel coronavirus pneumonia (COVID-19) patients: a medical records based retrospective study

Effect of high dose intravenous vitamin C on moderate novel coronavirus pneumonia (COVID-19) patients: a medical records based retrospective study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000033050
Enrollment
Unknown
Registered
2020-05-18
Start date
2020-05-04
Completion date
Unknown
Last updated
2020-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Experimental group:high dose intravenous vitamin C
control group:without high dose intravenous vitamin C

Sponsors

Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients who was diagnosed with COVID-19 pneumonia with severe and critical severity. Diagnosis were performed according to World Health Organization interim guidance11. 2. Aged > 18 years old.

Exclusion criteria

Exclusion criteria: 1. During the treatment, the tumor occurred; 2. During pregnancy or lactation; 3. Under the treatment of other testing drug.

Design outcomes

Primary

MeasureTime frame
C-reactive protein;temperature;Erythrocyte sedimentation rate;Lymphocyte;CD4+ T cell;PaO2/FiO2;D-dimer;Platelets;SOFA score;Serum lactate dehydrogenase;Total bilirubin;Creatinine;Prealbumin;—

Countries

China

Contacts

Public ContactEnqiang Mao

Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine

maoeq@yeah.net+86 13501747906

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026